Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Myosana Therapeutics is raising $6,400,479.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nicholas Whitehead played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Myosana Therapeutics

Myosana Therapeutics, Inc. is pioneering efforts in developing non-viral targeted gene therapy for skeletal muscle and cardiac diseases. Our current focus is Duchenne muscular dystrophy (DMD) but our platform is applicable to any genetic muscle disease. Current gene therapy for skeletal and cardiac muscle diseases uses Adeno Associated Virus (AAV) to deliver small healthy genes or portions of large genes, to the cells that contain unhealthy (mutated) genes. AAV has numerous limitations, including limited gene size capacity (5 kilobases), precluding its use for many larger genes like dystrophin. Furthermore, many individuals may have naturally occurring antibodies against AAV or will develop antibodies after their first treatment, limiting treatment to a single dose.

To learn more about Myosana Therapeutics, visit http://myosanatherapeutics.com/

Contact:
Nicholas Whitehead, Chief Executive Officer
https://www.linkedin.com/in/nick-whitehead-26498995/
206-465-3004

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved